1.50 "Initial Indication" means the first indication for which the Product receives Marketing Approval in the Territory, which the Parties expect to be treatment of adult patients with locally advanced or metastatic urothelial carcinoma which has (a) susceptible FGFR 3 or 2 genetic alterations and (b) progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, where patients are selected for therapy based on an FDA-approved companion diagnostic for the Product; provided, however, that, with respect to any such indication for which the Product receives Marketing Approval from the FDA, "Initial Indication" shall be defined by the exact wording used in the Product Label and Insert as so approved. 1.51 "Janssen" has the meaning set forth in the preamble to this Agreement. 1.52 "Janssen Brand Usage Guidelines" means Janssen's group guidelines on the Janssen brand visual and verbal identity as they apply to the Trademarks of Janssen and its Affiliates and the use of other companies' names and logos, as notified to Company by Janssen from time to time. 1.53 "Janssen Indemnified Parties" has the meaning set forth in Section 12.1.2. 1.54 "Joint Commercial Team" has the meaning set forth in Section 4.2.1. 1.55 "Launch Date" means the date of the commercial launch of the Product in the Territory selected by Janssen. As of the Effective Date, the Parties expect that the Launch Date shall be on or about May 1, 2019. 1.56 "Laws" means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law in any country, state, province, county, city or other political subdivision, and includes any rule or regulation of any Governmental Authority that may be in effect from time to time in the Territory. 1.57 "License Agreement" means that certain